AstraZeneca, Pharma Laggard, Shaking Up Its R&D Team
The meager pipelines and R&D setbacks plaguing the pharmaceutical industry have prompted two of the largest drugmakers to shake up their operations today. Roche hired John Reed, who heads the Sanford-Burnham Medical Research Institute in California, to take over as head of its Pharma Research and Early Development unit, replacing Mike Burgess. And AstraZeneca (AZN) announced that R&D head Martin Mackay is leaving.
In fact, the moves at AstraZeneca are more widespread than just R&D as Tony Zook, who had been executive vp for global commercial activities, is also leaving. As part of the shake up, AstraZeneca is also creating several new R&D and commercial positions, including a new executive job that will be responsible for global portfolio and product strategy, in hopes of “bridging” R&D and sales.
The moves reflect the frustration that many large drugmakers have encountered in recent years as they muddle through the patent cliff – the moment when big-selling meds lost patent protection and face generic rivals; laboratory setbacks; regulatory hurdles and an increasingly competitive scramble to acquire or license compounds or simply purchase smaller companies.
AstraZeneca’s record in Pharma R&D is one of the worst in the industry.
At AstraZeneca, former Roche exec Pascal Soriot has made his biggest move since joining the drugmaker as CEO last summer. But AstraZeneca has needed some big changes. Under his predecessor, Dave Brennan, AstraZeneca languished and was relying on a variety of licensing deals, partnerships and acquisitions to replenish its pipeline. There was also the failure of the $15 billion acquisition of MedImmune six years ago to yield any results.
And so, Soriot is trying to not only bolster R&D, but to create a structure in which discovery and development is more closely aligned with commercial possibilities, a concept that is regularly discussed in the pharmaceutical industry, but imperfectly executed. His plan calls for creating three senior R&D roles responsible for discovery and early stage development in small molecules; discovery and early stage development in biologics; and late stage development. There will also be three new commercial jobs representing North America, Europe and International.
“This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making,” Soriot says in a brief statement.
To read the remainder of this article, go to Pharmalot.
Ed Silverman, a contributing editor of YCharts, is the founder and editor of Pharmalot. He previously reported on the pharmaceutical industry and other business topics for the Star-Ledger of New Jersey, New York Newsday and Investor’s Business Daily. He can be reached at firstname.lastname@example.org.
Read more articles about: Company Analysis
Timeless thoughts for serious business minds
- pharma stocks
- tech stocks
- money managers
- stocks that look cheap
- stocks that look pricey
- retail stocks
- growth stocks
- earnings season
- dividend growth
- energy stocks
- bank stocks
- short sellers
- warren buffett
- value investing
- executive compensation
- entertainment stocks
- Federal Reserve
- overall market
- stock screener
- cyclical stocks
- fast food stocks
- stock that look pricey